Regulatory Status: Sermorelin was FDA-approved in 1997 for the diagnosis and treatment of pediatric growth hormone deficiency. It was voluntarily withdrawn from the US commercial market in 2008 — not for safety reasons, but due to commercial decisions by the manufacturer. It is currently available only through licensed compounding pharmacies with a valid prescription. It is not FDA-approved for adult anti-aging, body composition, or general wellness applications.
What Is Sermorelin?
Sermorelin is a synthetic version of the first 29 amino acids of growth hormone-releasing hormone (GHRH 1-29), the peptide your hypothalamus produces to signal the pituitary to release growth hormone. Rather than introducing exogenous GH directly into the body, Sermorelin works upstream — it asks your pituitary to do its job.
This distinction matters. Exogenous HGH bypasses the body's feedback loop entirely, which is why it carries greater risk of side effects and suppression. Sermorelin preserves the regulatory system: if GH levels are already adequate, the pituitary simply won't respond as strongly. The body self-limits.
How It Compares to CJC-1295 and Ipamorelin
CJC-1295 (especially with DAC) is a modified GHRH analog engineered for a much longer half-life — up to eight days. That sustained elevation in GH can produce faster results but also means you lose the natural pulsatile pattern your body uses to regulate GH secretion. Sermorelin, with its 10–20 minute half-life, creates a sharp pulse and then clears quickly, mimicking what the body actually does.
Ipamorelin is a GHRP (growth hormone-releasing peptide) — it works through a different receptor (ghrelin receptor) and is often stacked with CJC-1295 for synergistic effect. Sermorelin operates alone on the GHRH receptor. Sermorelin is generally considered the more conservative option: lower ceiling, lower risk, and more physiologically faithful than modern DAC-modified analogs.
Reported Effects
Clinical users and wellness prescribers report a range of effects that emerge gradually over 3–6 months of consistent use. These include improved body composition (reduced fat mass, modest lean mass support), faster recovery from training, deeper and more restorative sleep, improved skin texture and collagen quality, and increased energy and mood stability.
None of these are overnight changes. Sermorelin works by nudging the pituitary back toward more youthful output levels — it doesn't flood the system. The timeline reflects that mechanism. Users who expect dramatic results in weeks typically abandon it before it's had time to work.
Timing Is Everything
Of all the variables in a Sermorelin protocol, injection timing has the most impact on whether you see results at all. The natural GH pulse occurs early in the night, approximately 1–2 hours after falling asleep. Injecting Sermorelin before bed — when growth hormone is already primed to release — amplifies that pulse rather than fighting against the circadian pattern.
The other critical rule: insulin blunts GH release. Elevated insulin from a recent meal or carbohydrate intake will significantly dampen the GH pulse Sermorelin is trying to trigger. The practical guideline is to avoid carbohydrates and sugars for 2–3 hours before injection. A late-night snack, even a "healthy" one with carbs, can negate the dose entirely. Fasted injection on a pre-sleep stomach is what separates effective Sermorelin use from wasted doses.
In short: inject before bed, on an empty stomach, no carbs for 2–3 hours prior. That single habit accounts for the majority of the difference between people who report strong results and those who see nothing.
2026 Regulatory Context
Sermorelin Remains Legally Compoundable (2026): Unlike many research peptides that were placed on the FDA's restricted Category 2 list in 2023, Sermorelin has remained available through licensed US compounding pharmacies throughout the 2023–2026 regulatory period. It was never placed on the Category 2 safety-concern list. This distinguishes it from CJC-1295 and Ipamorelin, which were restricted in 2023 and remain unavailable through licensed US compounding channels as of September 2026. In April 2026, HHS Secretary RFK Jr. removed 12 peptides from the FDA's Category 2 list (including BPC-157 and TB-500) and sent them to PCAC for scientific review beginning July 2026 — a process with no guaranteed outcome, given PCAC voted against every compound it reviewed in 2024. Separately, in July 2026, an FDA advisory committee voted to recommend BPC-157, TB-500, and several other peptides for addition to the 503A compounding list; formal FDA rulemaking is required before any of these become legally compoundable, expected no earlier than mid-2027. None of this affects Sermorelin. For patients seeking a legal GHRH-class peptide from a licensed U.S. compounding pharmacy, Sermorelin remains the only currently available option as of September 2026.
Sermorelin on ShedPilot
ShedPilot includes a dedicated Sermorelin track that builds your nutrition timing around your injection protocol. The app understands the GH-insulin interaction and structures evening meals to ensure you're in the optimal metabolic state at injection time — without requiring you to track it manually.
If you're using Sermorelin alongside a GLP-1 medication, the ShedPilot app integrates both protocols and helps you navigate the specific dietary timing each one requires.